Repare Therapeutics has emerged from stealth mode with an impressive $68 million.

Vineti is launching its cloud-based system to streamline company processes and accelerate patient access to cell and gene therapies.

Theranos and Walgreens have reached a tentative agreement to put the latter's breach-of-contract lawsuit to rest, WSJ sources say.

Sarepta Therapeutics has penned its second DMD gene therapy pact this year.

ImmunoCellular Therapeutics has suspended a phase 3 trial of its lead cancer vaccine after failing to raise the funds it needs to complete the study.

The FDA is working on a medical innovation development plan to lower healthcare costs by streamlining the path to market for targeted therapies.

Syntimmune has got off a beefy $50 million series B round.

Rubius Therapeutics has raised $120 million to take two of its off-the-shelf red blood cell therapies into the clinic.

German Merck and R&D charity CRUK are coming together to launch a biotech focused on immuno-oncology.

EvaluatePharma has totted up the figures for R&D spend and costs for biopharmas, and the figures are huge.